Clinical Trial Update: [18F]APN-1607 PET in Subjects With AD Compared to HC [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the PET radiotracer [18F]APN-1607 in Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease versus healthy cont…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment Due to Alzheimer Disease

Drugs mentioned

• [18F]APN-1607 (APN-1607)

Snippet

Sponsor: APRINOIA Therapeutics | Conditions: Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 3 | Status: COMPLETED